NCT05933187

A Study Evaluating the Pharmacokinetics and Relative Bioavailability of Emraclidine Immediate-Release Tablets in Healthy Adult Participants

A Phase 1, Open-label Trial to Evaluate the Pharmacokinetics and Relative Bioavailability of Emraclidine Following a Single Oral Administration of Immediate-Release Tablets in Healthy Adult Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 15 (actual)
• Sponsor: Cerevel Therapeutics, LLC · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this trial is to evaluate plasma concentrations of emraclidine following single dose oral administration of different emraclidine immediate release (IR) tablets in healthy participants.

Conditions

• Healthy Participants

Interventions

Type	Name	Description
DRUG	Treatment A: Emraclidine 30mg IR tablets (reference)	IR oral tablets
DRUG	Treatment B: Emraclidine 30mg IR test tablets 1	IR oral tablets
DRUG	Treatment C: Emraclidine 30mg IR test tablets 2	IR oral tablets
DRUG	Treatment D: Emraclidine 30mg IR test tablets 3	IR oral tablets

Timeline

• Start date: 2023-07-19
• Primary completion: 2023-09-12
• Completion: 2023-09-12
• First posted: 2023-07-06
• Last updated: 2023-11-24

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study